Health News Releases

  • Today March 28
December 02, 2022 15:25
New Crown Bioscience Publication Details Application of In Vitro 3D Organoids with Matched PDX for Clinically Relevant Oncology Drug Development
Crown Bioscience, a JSR Life Sciences company and Contract Research Organization (CRO), has announced the publication of its review paper entitled: Translational and Clinical Relevance of PDX-Derived
December 02, 2022 14:55
Sermo Survey Finds Opportunity to Educate General Care Physicians on PrEP to Increase Patient Adoption Nearly Half of General Care Physicians Reported They Do Not Have Enough Knowledge About PrEP Options to Discuss with Patients
Timed to World AIDS Day, Sermo, a physician-first online community and leader in global HCP insights, released a new survey that found 46% of general care physicians including PCPs, OB-GYNs, and pedia
December 02, 2022 09:20
Ferring Receives U.S. FDA Approval for REBYOTA® (fecal microbiota, live-jslm) - A Novel First-in-Class Microbiota-Based Live Biotherapeutic
Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTA® (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicat
December 01, 2022 09:50
AGIC Capital Acquires Majority Stake in ATEC Pharmatechnik GmbH
AGIC Capital (“AGIC”), a growth-oriented private equity firm with $2.2 billion of assets under management, today announced that it had acquired a majority stake in ATEC Pharmatechnik GmbH (“ATEC” or “
December 01, 2022 09:50
ANANDA Scientific Announces FDA Approval of the IND for a Clinical Trial exploring treatment of Social Anxiety Disorder (SAD)
ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nanth
December 01, 2022 09:40
New Prospective Study Finds That Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring Can Help Provide Effective Blood Management in Patients Undergoing Major Surgery
Masimo (NASDAQ: MASI) today announced the findings of a prospective, double-blinded, randomized, controlled trial published in the Journal of the College of Physicians and Surgeons Pakistan. In the st
December 01, 2022 09:40
ViiV Healthcare Unveils a New Global Study Revealing Three Quarters of People Believe There Are Still Negative Perceptions When It Comes to People Living With HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from a perceptions survey which unveils a widespread gap in
November 30, 2022 10:20
Kaneka to Manufacture and Supply Intermediates for Shionogi COVID-19 Drug
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) will manufacture and supply intermediates to Shionogi & Co., Ltd. (Headquarters: Chuo-ku, Osaka; Chief Executive Officer:
November 30, 2022 10:10
Sonic Healthcare Acquires Strategic Stake in Microba Life Sciences, Establishes Significant Commercial Partnership
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited (ASX: SHL) (“Sonic”) has agreed to inves
November 29, 2022 13:20
LevitasBio Strengthens its C-Suite
LevitasBio, Inc., a premier end-to-end sample processing and cellular analysis provider to the life sciences market, announced the hiring of Dominique Remy-Renou as its Senior Vice President of Global
November 28, 2022 16:05
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients
Regulatory News: CSL Vifor and Fresenius Kabi today announced that China’s National Medical Products Administration (NMPA) has approved Ferinject®, a preparation for intravenous iron therapy for th
November 28, 2022 14:00
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant A
November 25, 2022 15:35
Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously
Regulatory News: Tomorrow is Iron Deficiency Day. For the eighth consecutive year, CSL Vifor is supporting a growing alliance of international organizations including the Heart Failure Policy Netwo
November 23, 2022 16:50
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review of the Biologics License Application (BLA) for TAK-003, the company
November 22, 2022 13:45
Merck Aims to Double R&D Productivity in Oncology, Neurology and Immunology to Deliver More Medicines to Patients Faster
Merck, a leading science and technology company, today shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity. To achieve the goal of introduc
November 21, 2022 16:10
DentalMonitoring Files Patent Infringement Lawsuit Asserting Three Patents Against Align Technology
DentalMonitoring SAS, the inventor of the world’s first AI-driven remote monitoring and analysis solution for orthodontics, today announced that it has filed a patent infringement lawsuit against Alig
November 21, 2022 13:45
Monrol and FutureChem Announced a Clinical Supply Partnership
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) is delighted to announce that it has reached an agreement in principal with FutureChem based in Seoul, South Korea, a radiopharmaceutical company, for t
November 21, 2022 11:55
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
Takeda (TSE:4502/NYSE:TAK) today announced that the randomized, Phase 3 PhALLCON trial met its primary endpoint, demonstrating that adult patients with newly-diagnosed Philadelphia chromosome-positive
DEXLEVO at AMWC JAPAN: a Successful Debut
November 21, 2022 09:45
DEXLEVO at AMWC JAPAN: a Successful Debut
DEXLEVO, a company specializing in beauty medical devices, attended the Aesthetic and Anti-Aging Medicine World Congress (AMWC Japan) held for the first time in Japan. AMWC is one of the world’s three
November 18, 2022 16:40
The New England Journal of Medicine and NEJM Group partner with Wolters Kluwer to expand global reach of leading journals
Wolters Kluwer Health and NEJM Group have entered into an exclusive partnership to ensure that more researchers and clinicians around the world can access the growing family of NEJM Group journals. Bu
November 18, 2022 16:20
ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer
ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-cancer and anti-fibrotic therapies, today announces that the first patient has been dose
November 18, 2022 15:30
Neuraptive Therapeutics, Inc. Announces Appointment of Leading Industry Executive, Dr. Robert R. Ruffolo as New Director to the Board
Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by nerve injuries,
GE Healthcare Announces $80 Million Investment To Expand Contrast Media Production Capacity
November 18, 2022 14:30
GE Healthcare Announces $80 Million Investment To Expand Contrast Media Production Capacity
GE Healthcare’s Pharmaceutical Diagnostics business announced an $80 million investment to increase manufacturing capacity by 30 percent at its Active Pharmaceutical Ingredients (API) site in Lindesne
November 16, 2022 11:20
Medidata Launches Rave Companion, the First Scalable Solution for Automating EHR Data Entry into Rave EDC
Medidata, a Dassault Systèmes company, today announced plans to launch Rave Companion, an innovative, scalable, patent pending technology helping clinical trial sites save time and reduce errors in tr
The GICELL presents preclinical data of T.O.P. NK at SITC in Boston, MA, USA. (Photo provided by GIC
November 16, 2022 11:06
GICELL Proves Excellent Anti-tumor Efficacy in Various Solid Tumor-bearing Animal Model
GICELL announced the data from the preclinical studies on T.O.P. NK (Tumor targeting, Optimally Primed NK), an allogeneic NK cell therapy which had been presented at the Society for Immunotherapy of C
25 per page50 per page75 per page100 per page